________________________________________________________________________________________________________________________________

(C) SOBI 2013 - Philip WoodPhilip Wood to Push Haemophilia Business of Swedish Orphan Biovitrum and Biogen Idec*

November 2013. Stockholm specialty pharma Swedish Orphan Biovitrum AB (“SOBI”) has been promoting Philip Wood to head its Commercial Therapeutic Area Haemophilia. The nomination precedes planned market launch of Biogen Idec’s products from its monomeric Fc fusion protein technology platform. Today SOBI announced that its development partner will start sales of long-lasting rFVIIIFc (trade name: “Eloctate”) in the United States mid-2014. Since beginning of October Biogen Idec is promoting genetic testing to people with hemophilia through a partnership with three American advocacy and treatment organisations: National Hemophilia Foundation, the American Thrombosis and Hemostasis Network and the Puget Sound Blood Center, a concerted marketing effort which SOBI will have to mirror in Europe and for which the Swedish company puts Mr. Wood in place. According to SOBI Mr. Wood will primary be based at Stockholm to lead the Haemophila Area Team.

Swedish Orphan Biovitrum/Biogen Idec Hemophilia Pipeline 11.2013

Philip Wood (1968) obtained a Bachelor of Science in Geology from University of Southampton (UK) in 1989. In 2002 he earned a certificate of the Chartered Institute of Marketing and a degree for “Global Positioning” from the Wharton School at the University of Pennsylvania in 2010. He initially worked in sales and restoration of classic cars. In January 1994 he started his career in the pharmaceutical industry as medical representative with American Cyanamid (just becoming American Home Products, then Wyeth which was later acquired by Pfizer). Since then he was in marketing and sales with increasing responsibilities, lately for rare gentic diseases resp. the European haemophilia franchise. In March 2012 Mr. Wood joined Swedish Orphan Biovitrum at Stockholm in the Global Strategic Lead Unit responsible for Europe. ed

Copyright Notice
Please note: You may freely distribute the link to this article. Any copying, distributing, or publishing of the entire article or parts of it (picture included) requires prior written consent by B2Bioworld or by third parties retaining copyrights. All rights reserved.

This editorial article is brought to you free of charge. You may see how we work, investigate issues,
and write up results in articles free of advertising and normally at cost . Enjoy reading

Back to section

Related Editorial Articles

Make or Break Drug Discovery and Biopharma of Merck Life Science
Andrew Bulpin, currently Global Head of Merck Millipore Process Solutions on strategy and the road ahead. Includes competitive rank of Merck Life Science Division

Network intelligence for Lundbeck’s new drugs
Time is tight for Andreas Eggert and Barbara Jaszewski

Novo Nordisk: Doing our business a little bit differently than the others in industry
Mads Krogsgård Thomsen on business models different to competitors like Eli Lilly, Pfizer, or Eli Lilly, Sanofi-Aventis. The case of stem cell therapeutics

Horizon Discovery: Mitigating risks and developing the U.S. business

Pfizer Regenerative Medicine (Neusentis): It really started last year…
Ruth McKernan, global CSO of Pfizer’s Regenerative Medicine Unit (today Neusentis) addresses basic and practical issues in pharmaceutical research on stem cells

Systems Biology Applied
Rudi Balling, Director of the Luxembourg Centre for Systems Biomedicine, on the need of systems theory thinking in using technologies and pitfalls of some concepts

Metrics for Disease, Health, and Wellness
Personalized medicine? A systems look at human genetic diagnostics and the road ahead for next-generation sequencing by Leroy Hood, Institute for Systems Biology at Seattle

Patient-centered Precision Care
Michael Christman, President of Coriell Institute on turning research on human genotyping into healthcare routine and attracting payors